Cargando…

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model

PURPOSE: To develop an oral formulation of amphotericin B (AmB) that is stable at the temperatures of WHO Climatic Zones 3 and 4 (30–43°C) and to evaluate its efficacy in a murine model of visceral leishmaniasis (VL). METHODS: The stability testing of four novel oral lipid AmB formulations composed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasan, Ellen K., Gershkovich, Pavel, Zhao, Jinying, Zhu, Xiaohua, Werbovetz, Karl, Tidwell, Richard R., Clement, John G., Thornton, Sheila J., Wasan, Kishor M.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998436/ https://www.ncbi.nlm.nih.gov/pubmed/21151883 http://dx.doi.org/10.1371/journal.pntd.0000913

Ejemplares similares

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
por: Sivak, Olena, et al.
Publicado: (2011)

In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
por: Leon, Carlos G, et al.
Publicado: (2011)

Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis
por: Ibrahim, Fady, et al.
Publicado: (2013)

Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections
por: Wasan, Ellen, et al.
Publicado: (2022)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
por: Cuddihy, Grace, et al.
Publicado: (2019)

Effects of climate change on soil health resulting in an increased global spread of neglected tropical diseases
por: Wasan, John Paul M., et al.
Publicado: (2023)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
por: Shahnaz, Gul, et al.
Publicado: (2017)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
por: Fakiola, Michaela, et al.
Publicado: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study
por: Sundar, Shyam, et al.
Publicado: (2014)

Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet
por: Sivak, Olena, et al.
Publicado: (2009)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
por: Hasnain, Md Golam, et al.
Publicado: (2018)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome
por: Gershkovich, Pavel, et al.
Publicado: (2015)

Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism
por: Thornton, Sheila J, et al.
Publicado: (2008)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
por: Mudavath, Shyam Lal, et al.
Publicado: (2014)

Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B
por: McQuarrie, Shauna, et al.
Publicado: (2015)

Analytical Strategies to Analyze the Oxidation Products of Phytosterols, and Formulation-Based Approaches to Reduce Their Generation
por: Gachumi, George, et al.
Publicado: (2021)

Formulation and characterisation of a self‐nanoemulsifying drug delivery system of amphotericin B for the treatment of leishmaniasis
por: Khan, Momin, et al.
Publicado: (2019)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

Dietary supplementation with phytosterol and ascorbic acid reduces body mass accumulation and alters food transit time in a diet-induced obesity mouse model
por: Thornton, Sheila J, et al.
Publicado: (2011)

Visceral Leishmaniasis and Immunocompromise as a Risk Factor for the Development of Visceral Leishmaniasis: A Changing Pattern at The Hospital for Tropical Diseases, London
por: Fletcher, Kate, et al.
Publicado: (2015)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis
por: Vale, Danniele L., et al.
Publicado: (2023)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Ocular Leishmaniasis Treated by Intralesional Amphotericin B
por: Nikandish, Malihe, et al.
Publicado: (2016)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2016)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

ICOS signaling limits regulatory T cell accumulation and function in visceral adipose tissue
por: Mittelsteadt, Kristen L., et al.
Publicado: (2021)

Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff
por: Maintz, Eva-Maria, et al.
Publicado: (2014)

Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
por: Asad, Mohammad, et al.
Publicado: (2015)

A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure
por: Eichenberger, Anna, et al.
Publicado: (2017)

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g402mvgtsuftuhjso455cnn9ve